Retrospective Comparison of Levofloxacin and Moxifloxacin on Multidrug-Resistant Tuberculosis Treatment Outcomes
![]() |
Lee, Jin-Woo
(Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine)
Lee, Chang-Hoon (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center) Kim, Deog-Kyeom (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center) Yoon, Ho-Il (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University Bundang Hospital, Seoul National University College of Medicine) Kim, Jae-Yeol (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chung-Ang University College of Medicine) Lee, Sang-Min (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine) Yang, Seok-Chul (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine) Lee, Jae-Ho (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University Bundang Hospital, Seoul National University College of Medicine) Yoo, Chul-Gyu (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine) Lee, Choon-Taek (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University Bundang Hospital, Seoul National University College of Medicine) Chung, Hee-Soon (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center) Kim, Young-Whan (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine) Han, Sung-Koo (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine) Yim, Jae-Joon (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine) |
1 | Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003;47:653-657. DOI ScienceOn |
2 | Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998;42:2066-2069. |
3 | Miyazaki E, Miyazaki M, Chen JM, Chaisson RE, Bishai WR. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 1999;43:85-89. DOI ScienceOn |
4 | Veziris N, Truffot-Pernot C, Aubry A, Jarlier V, Lounis N. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 2003;47:3117-3122. DOI ScienceOn |
5 | McMurray DN. Disease model: pulmonary tuberculosis. Trends Mol Med 2001;7:135-137. DOI ScienceOn |
6 | JI B, Lounis N, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995;39:1341-1344. DOI ScienceOn |
7 | Shandil RK, Jayaram R, Kaur P, et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 2007;51:576-582. DOI ScienceOn |
8 | Flynn JL, Capuano SV, Croix D, et al. Non-human primates: a model for tuberculosis research. Tuberculosis (Edinb) 2003;83:116-118. DOI ScienceOn |
9 | Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006;10:605-612. |
10 | World Health Organization. Multidrug and extensively drug-resistant tuberculosis: 2010 global report on surveillance and response. Geneva: World Health Organization, 2010. |
11 | Berning SE. The role of fluoroquinolones in tuberculosis today. Drugs 2001;61:9-18. DOI ScienceOn |
12 | van den Boogaard J, Kibiki GS, Kisanga ER, Boeree MJ, Aarnoutse RE. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 2009;53:849-862. DOI ScienceOn |
13 | Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007;67:2077-2099. DOI ScienceOn |
14 | World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2008. |
15 | Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003;3:432-442. DOI ScienceOn |
16 | Pletz MW, De Roux A, Roth A, Neumann KH, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004;48:780-782. DOI ScienceOn |
17 | Jacobs MR. Activity of quinolones against mycobacteria. Drugs 1999;58 Suppl 2:19-22. |
18 | Rastogi N, Goh KS, Bryskier A, Devallois A. In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996;40:1610-1616. |
19 | Yew WW, Chan CK, Leung CC, et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003;124:1476-1481. DOI ScienceOn |
20 | Yew WW, Chan CK, Chau CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000;117:744-751. DOI ScienceOn |
21 | Hwang SS, Kim HR, Kim HJ, et al. Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB. Eur Respir J 2009;33:581-585. DOI ScienceOn |
22 | Kim HR, Hwang SS, Kim HJ, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patient s with multidrug-resistant tuberculosis. Clin Infect Dis 2007;45:1290-1295. DOI ScienceOn |
23 | Kim DK, Park GM, Hwang YI, et al. Microarray analysis of gene expression associated with extrapulmonary dissemination of tuberculosis. Respirology 2006;11:557-565. DOI ScienceOn |
24 | Kim HJ, Kang CH, Kim YT, et al. Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis. Eur Respir J 2006;28:576-580. DOI ScienceOn |
25 | Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005;9:640-645. |
26 | Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005;365:318-326. |
27 | Frieden TR, Sherman LF, Maw KL, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996;276:1229-1235. DOI ScienceOn |
28 | Mukherjee JS, Rich ML, Socci AR, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004;363:474-481. DOI ScienceOn |
29 | Chiang CY, Enarson DA, Yu MC, et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J 2006;28:980-985. DOI ScienceOn |
30 | Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662. DOI ScienceOn |
![]() |